TY - JOUR
T1 - Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia
AU - Canales, Patricia L.
AU - Olsen, Jerry
AU - Miller, Alexander L.
AU - Crismon, M. Lynn
N1 - Funding Information:
This work was supported in part by grants from the Texas Department of Mental Health and Mental Retardation and from the Friends for Psychiatric Research (San Antonio).
PY - 1999
Y1 - 1999
N2 - Since the introduction of phenothiazines in the 1950s, clinicians have used antipsychotics in combination. This practice has previously been declared irrational as traditional antipsychotics were thought to work by similar mechanisms. However, the advent of the atypical antipsychotics provides a cadre of new medications with varying pharmacodynamic profiles. Once again, the potential use of combination antipsychotic therapy is being explored. Potential advantages of combination antipsychotics include the possibility of increased efficacy in patients with treatment-resistant symptoms, enhanced effect on agitation and positive symptoms in acutely psychotic individuals, and decreased withdrawal symptoms in patients being converted from one antipsychotic to another. Recommendations for clinical guidelines for antipsychotic combinations are limited at present by inadequate efficacy and safety data and clinical experience regarding optimal use.
AB - Since the introduction of phenothiazines in the 1950s, clinicians have used antipsychotics in combination. This practice has previously been declared irrational as traditional antipsychotics were thought to work by similar mechanisms. However, the advent of the atypical antipsychotics provides a cadre of new medications with varying pharmacodynamic profiles. Once again, the potential use of combination antipsychotic therapy is being explored. Potential advantages of combination antipsychotics include the possibility of increased efficacy in patients with treatment-resistant symptoms, enhanced effect on agitation and positive symptoms in acutely psychotic individuals, and decreased withdrawal symptoms in patients being converted from one antipsychotic to another. Recommendations for clinical guidelines for antipsychotic combinations are limited at present by inadequate efficacy and safety data and clinical experience regarding optimal use.
UR - http://www.scopus.com/inward/record.url?scp=0032828874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032828874&partnerID=8YFLogxK
U2 - 10.2165/00023210-199912030-00002
DO - 10.2165/00023210-199912030-00002
M3 - Review article
AN - SCOPUS:0032828874
SN - 1172-7047
VL - 12
SP - 179
EP - 188
JO - CNS Drugs
JF - CNS Drugs
IS - 3
ER -